In a groundbreaking advancement at the intersection of artificial intelligence and neuro-oncology, a Harvard Medical School–led team has introduced a novel AI tool capable of discriminating between two visually similar yet biologically distinct brain tumors with unprecedented accuracy. Such an uncertainty-aware design is vital, given that over 100 brain tumor subtypes exist, many of which are rare and bear overlapping characteristics. Performance evaluations conducted across five hospitals spanning four countries demonstrated consistent outperformance of PICTURE relative to veteran neuropathologists and existing AI diagnostic frameworks. Though initially focused on glioblastoma and PCNSL differentiation, future iterations of the AI system might integrate genetic, molecular, and genomic data layers to refine tumor subclassification, prognostic predictions, and personalized therapy recommendations. Subject of Research: AI-based diagnostic differentiation of glioblastoma and primary central nervous system lymphoma during brain surgeryArticle Title: Uncertainty-aware ensemble of foundation models differentiates glioblastoma from its mimicsNews Publication Date: September 29, 2025Web References: https://www.nature.com/articles/s41467-025-64249-6References: DOI: 10.1038/s41467-025-64249-6Keywords: Artificial intelligence, Glioblastoma cells, Cancer, Brain tumors